Final results of a prospective, multicentre, randomized trial comparing 1, 3 or 6 infusions of Rituximab combined with 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular lymphoma (HD2000 trial)

被引：0
|
作者：
McClanahan, F. [1 ]
Hielscher, T. [2 ]
Rieger, M. [1 ]
Hensel, M. [3 ]
Bentz, M. [4 ]
Schmidt-Wolf, I [5 ]
Kaebisch, A. [6 ]
Salwender, H. [7 ]
Duerk, H. [8 ]
Staiger, H. [9 ]
Mandel, T. [10 ]
Neben, K. [1 ]
Hillengass, J. [1 ]
Ho, A. D. [1 ]
Witzens-Harig, M. [1 ]
机构：
[1] Univ Heidelberg, Heidelberg, Germany
[2] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany
[3] Onkol Schwerpunkt Praxis, Mannheim, Germany
[4] Stadtkrankenhaus Karlsruhe, Karlsruhe, Germany
[5] Univ Hosp Bonn, Bonn, Germany
[6] Facharztpraxis Innere Med, Giessen, Germany
[7] Asklepios Klin Altona, Hamburg, Germany
[8] St Marien Krankenhaus, Hamm, Germany
[9] Klinikum Mittelbaden, Baden Baden, Germany
[10] SLK Klin Heilbronn, Bad Friedrichshall, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：160 / 160
页数：1
相关论文
共 37 条
  • [1] How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial)
    McClanahan, Fabienne
    Hielscher, Thomas
    Rieger, Michael
    Hensel, Manfred
    Bentz, Martin
    Schmidt-Wolf, Ingo
    Kaebisch, Andreas
    Salwender, Hans-Juergen
    Duerk, Heinz
    Staiger, Hans Juergen
    Mandel, Thomas
    Neben, Kai
    Hillengass, Jens
    Ho, Anthony D.
    Witzens-Harig, Mathias
    BLOOD, 2009, 114 (22) : 1051 - 1052
  • [2] How much rituximab do we need: A multicenter, randomized trial comparing 1, 3 or 6 infusions of rituximab added to 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular non-Hodgkins lymphoma (HD2000-Trial).
    Hensel, M
    Scheuer, L
    Salwender, H
    Finke, J
    Buerkle, D
    Duerk, HA
    Kaebisch, A
    Naumann, R
    Staiger, HJ
    Schmidt-Wolf, I
    Kornacker, M
    Leo, E
    Fischer, J
    Ho, AD
    BLOOD, 2004, 104 (11) : 230B - 230B
  • [3] How much rituximab is needed for patients with follicular non-Hodgkins lymphoma:: A multicenter, randomized trial comparing 1, 3 or 6 infusions of rituximab added to 6 cycles of chop chemotherapy (HD2000-trial)
    Hensel, M
    Kornacker, M
    Salwender, H
    Staiger, H
    Schmidt-Wolf, I
    Dürk, H
    Käbisch, A
    Bürkle, D
    Krämer, A
    Finke, J
    Leo, E
    Fischer, J
    Ho, A
    ANNALS OF ONCOLOGY, 2005, 16 : 110 - 110
  • [4] Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma
    McClanahan, F.
    Hielscher, T.
    Rieger, M.
    Hensel, M.
    Bentz, M.
    Schmidt-Wolf, I.
    Kaebisch, A.
    Salwender, H.
    Duerk, H.
    Staiger, H.
    Mandel, T.
    Neben, K.
    Hillengass, J.
    Leo, E.
    Kraemer, A.
    Ho, A. D.
    Witzens-Harig, M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (10) : E68 - E71
  • [5] Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
    Merli, Francesco
    Luminari, Stefano
    Gobbi, Paolo G.
    Cascavilla, Nicola
    Mammi, Caterina
    Ilariucci, Fiorella
    Stelitano, Caterina
    Musso, Maurizio
    Baldini, Luca
    Galimberti, Sara
    Angrilli, Francesco
    Polimeno, Giuseppe
    Scalzulli, Potito Rosario
    Ferrari, Angela
    Marcheselli, Luigi
    Federico, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (11) : 1175 - +
  • [6] COMPARING INTENSITY OF CHEMOTHERAPY FOLLOWED PET-GUIDED RADIOTHERAPY IN PATIENTS WITH ADVANCED STAGE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD15 TRIAL
    Engert, M.
    Haverkamp, H.
    Kobe, C.
    Markova, J.
    Renner, C.
    Ho, A.
    Zijlstra, J.
    Kral, Z.
    Stein, H.
    Eich, H.
    Mueller, R. P.
    Dietlein, M.
    Borchmann, P.
    Diehl, V.
    HAEMATOLOGICA, 2012, 97 : 455 - 455
  • [7] Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with Rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: An interim analysis.
    Ladetto, M
    Ricca, I
    Benedetti, F
    Vitolo, U
    Liberati, M
    Musso, M
    Callea, V
    Gallamini, A
    Patti, C
    Pavone, V
    Almici, C
    Di Raimondo, F
    Fioritoni, G
    Olivieri, A
    Pogliani, EM
    De Souza, CA
    Majolino, I
    Boccadoro, M
    Gianni, AM
    Pileri, A
    Corradini, P
    Tarella, C
    BLOOD, 2002, 100 (11) : 307B - 307B
  • [8] Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab in poor-risk follicular lymphoma: early evaluation on treatment feasibility and response rate
    Ladetto, M
    Ricca, I
    Benedetti, F
    Liberati, M
    Vitolo, U
    Musso, M
    Gallamini, A
    Callea, V
    Pavone, V
    Almici, C
    Di Raimondo, F
    De Sousa, C
    Fioritoni, G
    Majolino, I
    Olivieri, A
    Patti, C
    Pogliani, E
    Astolfi, M
    Boccadoro, M
    Gianni, AM
    Corradini, P
    Tarella, C
    BONE MARROW TRANSPLANTATION, 2003, 31 : S7 - S8
  • [9] Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial
    Witzens-Harig, Mathias
    Benner, Axel
    McClanahan, Fabienne
    Klemmer, Jennifer
    Brandt, Julia
    Brants, Elke
    Rieger, Michael
    Meissner, Julia
    Hensel, Manfred
    Neben, Kai
    Dreger, Peter
    Lengfelder, Eva
    Schmidt-Wolf, Ingo
    Kraemer, Alwin
    Ho, Anthony D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (05) : 710 - 719
  • [10] Front - Line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma - Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG).
    Buske, Christian
    Kneba, Michael
    Lengfelder, Eva
    Pfreundschuh, Michael
    Ludwig, Wolf-Dieter
    Graeven, Ullrich
    Hallek, Michael
    Dreyling, Martin
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2006, 108 (11) : 146A - 147A
1234